Download MendeleyFunctional characterization of a PROTAC directed against BRAF mutant V600E.
Posternak, G., Tang, X., Maisonneuve, P., Jin, T., Lavoie, H., Daou, S., Orlicky, S., Goullet de Rugy, T., Caldwell, L., Chan, K., Aman, A., Prakesch, M., Poda, G., Mader, P., Wong, C., Maier, S., Kitaygorodsky, J., Larsen, B., Colwill, K., Yin, Z., Ceccarelli, D.F., Batey, R.A., Taipale, M., Kurinov, I., Uehling, D., Wrana, J., Durocher, D., Gingras, A.C., Al-Awar, R., Therrien, M., Sicheri, F.(2020) Nat Chem Biol 16: 1170-1178
- PubMed: 32778845
- DOI: https://doi.org/10.1038/s41589-020-0609-7
- Primary Citation of Related Structures:
6UUO - PubMed Abstract:
The RAF family kinases function in the RAS-ERK pathway to transmit signals from activated RAS to the downstream kinases MEK and ERK. This pathway regulates cell proliferation, differentiation and survival, enabling mutations in RAS and RAF to act as potent drivers of human cancers. Drugs targeting the prevalent oncogenic mutant BRAF(V600E) have shown great efficacy in the clinic, but long-term effectiveness is limited by resistance mechanisms that often exploit the dimerization-dependent process by which RAF kinases are activated. Here, we investigated a proteolysis-targeting chimera (PROTAC) approach to BRAF inhibition. The most effective PROTAC, termed P4B, displayed superior specificity and inhibitory properties relative to non-PROTAC controls in BRAF(V600E) cell lines. In addition, P4B displayed utility in cell lines harboring alternative BRAF mutations that impart resistance to conventional BRAF inhibitors. This work provides a proof of concept for a substitute to conventional chemical inhibition to therapeutically constrain oncogenic BRAF.
Organizational Affiliation:
Center for Molecular, Cell and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
